AVR 2.17% $11.25 anteris technologies ltd

Ann: Appendix 4C - quarterly, page-103

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 3,619 Posts.
    lightbulb Created with Sketch. 1041
    Great post Dazzer AND Eire.

    They may be different, but no-one sensible could say they're not well thought out and argued.

    There's no doubt that Adapt sales have been excruciatingly slow so far.
    Having said that though, the achievements of 2017 (TAVR patents lodged, regulatory approval for India, establishment of the 3D platform, commencement of nRAH contract, 4c contract, loan from PFG, WP signing on for 3 years) are MASSIVE.

    Personally I'm happy to buy the "hockey-stick" theorem for late 2018 Adapt sales for now. But I'll also be disappointed if US GPO tenders come to nothing.

    Meanwhile - TAVR progress, immunotherapies deal, new 3D products, approval of Chinese registration study, Australian TGA approval, new Adapt products, new engineering products, new Aust. hospital tenders... are all in the pipeline as well.

    All yours for 25c.

    Keep up the intelligent posting.
    Last edited by bottle: 31/01/18
 
watchlist Created with Sketch. Add AVR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.